176 related articles for article (PubMed ID: 36336526)
1. Cost-effectiveness of revised US pneumococcal vaccination recommendations in underserved minority adults < 65-years-old.
Wateska AR; Patricia Nowalk M; Lin CJ; Harrison LH; Schaffner W; Zimmerman RK; Smith KJ
Vaccine; 2022 Nov; 40(50):7312-7320. PubMed ID: 36336526
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness of Newly Recommended Pneumococcal Vaccination Strategies in Older Underserved Minority Adults in the USA.
Smith KJ; Wateska AR; Nowalk MP; Lin CJ; Harrison LH; Schaffner W; Zimmerman RK
Infect Dis Ther; 2022 Aug; 11(4):1683-1693. PubMed ID: 35831685
[TBL] [Abstract][Full Text] [Related]
3. Pneumococcal Vaccination Strategies in 50-Year-Olds to Decrease Racial Disparities: A US Societal Perspective Cost-Effectiveness Analysis.
Altawalbeh SM; Wateska AR; Nowalk MP; Lin CJ; Harrison LH; Schaffner W; Zimmerman RK; Smith KJ
Value Health; 2024 Jun; 27(6):721-729. PubMed ID: 38462225
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine in Argentinean Adults.
Rey-Ares L; Averin A; Mac Mullen M; Hariharan D; Atwood M; Carballo C; Huang L
Infect Dis Ther; 2024 Jun; 13(6):1235-1251. PubMed ID: 38700655
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analyses of 15- and 20-valent pneumococcal conjugate vaccines for Japanese elderly.
Hoshi SL; Shono A; Seposo X; Okubo R; Kondo M
Vaccine; 2022 Nov; 40(49):7057-7064. PubMed ID: 36273987
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of an in-development adult-formulated pneumococcal vaccine in older US adults.
Wateska AR; Nowalk MP; Lin CJ; Harrison LH; Schaffner W; Zimmerman RK; Smith KJ
Vaccine; 2023 Jul; 41(30):4431-4437. PubMed ID: 37316409
[TBL] [Abstract][Full Text] [Related]
7. Changes in the cost-effectiveness of pneumococcal vaccination and of programs to increase its uptake in U.S. older adults.
Wateska AR; Nowalk MP; Altawalbeh SM; Lin CJ; Harrison LH; Schaffner W; Zimmerman RK; Smith KJ
J Am Geriatr Soc; 2024 Jun; ():. PubMed ID: 38822745
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of adult pneumococcal vaccination policies in underserved minorities aged 50-64 years compared to the US general population.
Wateska AR; Nowalk MP; Lin CJ; Harrison LH; Schaffner W; Zimmerman RK; Smith KJ
Vaccine; 2019 Mar; 37(14):2026-2033. PubMed ID: 30846259
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness of Pneumococcal Vaccination in Adults in Italy: Comparing New Alternatives and Exploring the Role of GMT Ratios in Informing Vaccine Effectiveness.
Restivo V; Baldo V; Sticchi L; Senese F; Prandi GM; Pronk L; Owusu-Edusei K; Johnson KD; Ignacio T
Vaccines (Basel); 2023 Jul; 11(7):. PubMed ID: 37515068
[TBL] [Abstract][Full Text] [Related]
10. Health and economic outcomes of 20-valent pneumococcal conjugate vaccine compared to 15-valent pneumococcal conjugate vaccine strategies for adults in Greece.
Gourzoulidis G; Barmpouni M; Kossyvaki V; Vietri J; Tzanetakos C
Front Public Health; 2023; 11():1229524. PubMed ID: 37841729
[TBL] [Abstract][Full Text] [Related]
11. Higher-valency pneumococcal conjugate vaccines in older adults, taking into account indirect effects from childhood vaccination: a cost-effectiveness study for the Netherlands.
de Boer PT; van Werkhoven CH; van Hoek AJ; Knol MJ; Sanders EAM; Wallinga J; de Melker HE; Steens A
BMC Med; 2024 Feb; 22(1):69. PubMed ID: 38360645
[TBL] [Abstract][Full Text] [Related]
12. Cost-utility of 20-valent pneumococcal conjugate vaccine compared to no vaccination and recommended alternative vaccines among Belgian adults.
Marbaix S; Mignon A; Taelman A; Averin A; Atwood M; Vietri J
Expert Rev Vaccines; 2023; 22(1):1008-1021. PubMed ID: 37872765
[TBL] [Abstract][Full Text] [Related]
13. Cost-utility analysis of the use of the 20-valent anti-pneumococcal vaccine (PCV20) in adults older than 60 years in Spain.
Cantarero D; Ocaña D; Onieva-García MÁ; Rodríguez-García J; Gálvez P; Méndez C; Crespo C; López-Ibáñez de Aldecoa A
Vaccine; 2023 Aug; 41(36):5342-5349. PubMed ID: 37479615
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of the 20-valent pneumococcal conjugate vaccine versus the 23-valent pneumococcal polysaccharide vaccine for older adults in South Korea.
Kang DW; Kim CR; Song JY; Park SK
Vaccine; 2024 Feb; 42(4):871-878. PubMed ID: 38225184
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of PCV20 to Prevent Pneumococcal Disease in the Pediatric Population: A German Societal Perspective Analysis.
Ta A; Kühne F; Laurenz M; von Eiff C; Warren S; Perdrizet J
Infect Dis Ther; 2024 Jun; 13(6):1333-1358. PubMed ID: 38733494
[TBL] [Abstract][Full Text] [Related]
16. The impact and cost-effectiveness of pneumococcal immunisation strategies for the elderly in England.
Danelian G; Burton L; Bayley T; Sanchez-Marroquin A; Park J; Manley H; Choi Y; Andrews N; Ladhani S; Earnshaw A; Gritzfeld JF; Trotter C; Panovska-Griffiths J
Vaccine; 2024 Jul; 42(18):3838-3850. PubMed ID: 38763851
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of 20-valent pneumococcal conjugate vaccine in US infants.
Rozenbaum MH; Huang L; Perdrizet J; Cane A; Arguedas A; Hayford K; Tort MJ; Chapman R; Dillon-Murphy D; Snow V; Chilson E; Farkouh RA
Vaccine; 2024 Jan; 42(3):573-582. PubMed ID: 38191278
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine.
Smith KJ; Wateska AR; Nowalk MP; Raymund M; Nuorti JP; Zimmerman RK
JAMA; 2012 Feb; 307(8):804-12. PubMed ID: 22357831
[TBL] [Abstract][Full Text] [Related]
19. Pneumococcal Vaccine for Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023.
Kobayashi M; Pilishvili T; Farrar JL; Leidner AJ; Gierke R; Prasad N; Moro P; Campos-Outcalt D; Morgan RL; Long SS; Poehling KA; Cohen AL
MMWR Recomm Rep; 2023 Sep; 72(3):1-39. PubMed ID: 37669242
[No Abstract] [Full Text] [Related]
20. Cost-Effectiveness of Pneumococcal Vaccination Policies and Uptake Programs in US Older Populations.
Wateska AR; Nowalk MP; Lin CJ; Harrison LH; Schaffner W; Zimmerman RK; Smith KJ
J Am Geriatr Soc; 2020 Jun; 68(6):1271-1278. PubMed ID: 32086950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
